 |
|
|
| |
Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected, Virologically Suppressed, Older Adults at Week 96: Subgroup Analysis of a Randomized Switch Study (Study 311-1089)
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017)
23–26 July 2017 | Paris, France
Yazdan Yazdanpanah,1 Francois Raffi,2 Jacques Reynes,3 Margaret Johnson,4 Chloe Orkin,5 Nathan Clumeck,6 Brian Conway,7 Adriano Lazzarin,8 Franco Maggiolo,9 Martin Rhee10
1Hopital Bichat-Claude Bernard, Paris, France; 2Hotel-Dieu, Nantes, France; 3Hopital Gui de Chauliac, Montpellier, France; 4Royal Free London NHS
Foundation Trust, London, UK; 5Barts Health NHS Trust, Ambrose King Centre, Royal London Hospital, London, UK; 6CHU St-Pierre, Bruxelles,
Belgium; 7Vancouver Infectious Diseases Research & Care Centre Society, Vancouver, British Columbia, Canada; 8Ospedale San Raffaele, Milano,
Italy; 9Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 10Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
